22 mei 2012: of chemo nu al veel wordt toegepast met de liposomen techniek weten we niet, maar onderstaande twee studies geven daarover wel goede informatie.

18 september 2008: Bron:  1: Expert Rev Anticancer Ther. 2007 Jul;7(7):919-43.Click here to read Links

Wanneer borstkankerpatienten paclitacel krijgen toegediend verpakt in speciaal geprepareerde vetbolletjes (liposomen - Nab-paclitacel) dan blijkt de effectiviteit op ziektevrije tijd significant langer en met minder bijwerkingen dan alleen taxol intraveneus. Er lopen een aantal studies met speciaal op deze manier chemo toedienen bij verschillende soorten kanker en het blijkt een manier die echt effectiever is en minder belastend voor de kankerpatient. Hier de fase I studie bij borstkanker en daaronder een abstract hoe deze techniek werkt.


Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.

Adjunct Professor of Medicine, University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, CA 94143, USA. ichenderson@hotmail.com

Taxanes, paclitaxel and docetaxel, are among the most effective agents used to treat breast cancer. Nab-paclitaxel (ABI-007, Abraxane) is paclitaxel encapsulated in albumin. This differs from the more conventional formulation which uses cremophor to increase the solubility of paclitaxel (CrEL-paclitaxel). In a randomized trial that formed the basis of its regulatory approval in the USA, 3-weekly nab-paclitaxel induced a higher response rate and longer time to progression than CrEL-paclitaxel in patients with metastatic breast cancer. Except for grade 3 sensory neuropathy, nab-paclitaxel was also safer. An interim analysis from a more recent randomized Phase II trial suggests that weekly nab-paclitaxel is more effective and safer than either 3-weekly nab-paclitaxel or 3-weekly docetaxel. The superior efficacy of nab-paclitaxel is presumably due to the improved safety profile, which allows for the administration of higher doses, a greater proportion of which actually reaches the tumor. Observations on the development of nab-paclitaxel have important implications for our understanding of dose response in the use of cytotoxic drugs to treat all forms of cancer. Although it is not yet clear whether nab-paclitaxel can be routinely substituted for CrEL-paclitaxel or docetaxel in breast cancer treatment regimens, it seems highly likely that this will occur within the next 5 years.

PMID: 17627452 [PubMed - indexed for MEDLINE]


1: Int J Pharm. 2007 Jun 29;338(1-2):317-26. Epub 2007 Feb 13.Click here to read Links


Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.

College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.

An improved PEGylated liposomal formulation of paclitaxel has been developed with the purpose of improving the solubility of paclitaxel as well as the physicochemical stability of liposome in comparison to the current Taxol formulation. The use of 3% (v/v) Tween 80 in the hydration media was able to increase the solubility of drug. The addition of sucrose as a lyoprotectant in the freeze-drying process increased the stability of the liposome particles. There was no significant difference in the entrapment efficiency of paclitaxel between the conventional non-PEGylated liposomes and our PEGylated liposomes. Cytotoxicity in human breast cancer cell lines (MDA-MB-231 and SK-BR-3) of our paclitaxel formulation was less potent compared to Taxol after 24h incubation, but was equipotent after 72 h due to the slower release of drug from the liposome. Our PEGylated liposomes increased the biological half-life of paclitaxel from 5.05 (+/-1.52)h to 17.8 (+/-2.35)h compared to the conventional liposomes in rats. Biodistribution studies in breast cancer xenografted nude mouse model showed that our liposomes significantly decreased the uptake in reticuloendothelial system (RES)-containing organs (liver, spleen and lung) while increasing the uptake in tumor tissues after injection compared to Taxol or the conventional liposomal formulation. Moreover, the PEGylated liposome showed greater tumor growth inhibition effect in in vivo studies. Therefore, our PEGylated liposomal formulation of paclitaxel could serve as a better alternative for the passive targeting of human breast tumors.

PMID: 17368984 [PubMed - indexed for MEDLINE]


Plaats een reactie ...

Reageer op "Paclitaxel verpakt in speciaal verpakte vetbolletjes (liposomen - Nab-paclitaxel) geeft significant langere ziektevrije tijd en minder bijwerkingen dan taxol intraveneus bij borstkanker."

Gerelateerde artikelen